Jennison Associates’s AstraZeneca AZN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $126M | Buy |
666,497
+2,552
| +0.4% | +$480K | 0.08% | 127 |
|
|
2026
Q1 | $131M | Sell |
663,945
-1,017,478
| -61% | -$196M | 0.09% | 103 |
|
|
2025
Q4 | $309M | Sell |
1,681,423
-161,409
| -9% | -$28.3M | 0.19% | 55 |
|
|
2025
Q3 | $283M | Sell |
1,842,832
-4,240,851
| -70% | -$642M | 0.16% | 57 |
|
|
2025
Q2 | $850M | Buy |
6,083,683
+802,567
| +15% | +$112M | 0.5% | 40 |
|
|
2025
Q1 | $776M | Sell |
5,281,116
-2,434,366
| -32% | -$352M | 0.54% | 37 |
|
|
2024
Q4 | $1.01B | Buy |
7,715,482
+233,208
| +3% | +$32.6M | 0.61% | 39 |
|
|
2024
Q3 | $1.17B | Sell |
7,482,274
-1,029,554
| -12% | -$166M | 0.72% | 35 |
|
|
2024
Q2 | $1.33B | Sell |
8,511,828
-126,313
| -1% | -$19M | 0.85% | 30 |
|
|
2024
Q1 | $1.17B | Sell |
8,638,141
-228,130
| -3% | -$30.2M | 0.78% | 34 |
|
|
2023
Q4 | $1.19B | Sell |
8,866,271
-2,606,981
| -23% | -$339M | 0.89% | 31 |
|
|
2023
Q3 | $1.55B | Buy |
11,473,252
+569,647
| +5% | +$77.8M | 1.32% | 22 |
|
|
2023
Q2 | $1.56B | Buy |
10,903,605
+2,808,527
| +35% | +$413M | 1.28% | 22 |
|
|
2023
Q1 | $1.12B | Buy |
8,095,078
+5,447,651
| +206% | +$733M | 1.03% | 27 |
|
|
2022
Q4 | $359M | Buy |
2,647,427
+426,595
| +19% | +$53.5M | 0.36% | 52 |
|
|
2022
Q3 | $244M | Buy |
2,220,832
+163,169
| +8% | +$20.7M | 0.24% | 59 |
|
|
2022
Q2 | $272M | Buy |
2,057,663
+228,918
| +13% | +$30M | 0.27% | 56 |
|
|
2022
Q1 | $243M | Buy |
1,828,745
+418,787
| +30% | +$50.2M | 0.18% | 69 |
|
|
2021
Q4 | $164M | Sell |
1,409,958
-114,451
| -8% | -$13.5M | 0.1% | 88 |
|
|
2021
Q3 | $183M | Sell |
1,524,409
-11
| -0% | -$1.28K | 0.12% | 80 |
|
|
2021
Q2 | $183M | Buy |
1,524,420
+58,330
| +4% | +$6.4M | 0.12% | 80 |
|
|
2021
Q1 | $146M | Sell |
1,466,090
-3,496,545
| -70% | -$352M | 0.11% | 92 |
|
|
2020
Q4 | $496M | Sell |
4,962,635
-10,555,094
| -68% | -$1.12B | 0.35% | 50 |
|
|
2020
Q3 | $1.7B | Sell |
15,517,729
-4,049,139
| -21% | -$450M | 1.37% | 20 |
|
|
2020
Q2 | $2.07B | Buy |
19,566,868
+165,806
| +0.9% | +$17.1M | 1.87% | 16 |
|
|
2020
Q1 | $1.73B | Buy |
19,401,062
+1,074,083
| +6% | +$101M | 2.11% | 15 |
|
|
2019
Q4 | $1.83B | Buy |
18,326,979
+334,636
| +2% | +$31.5M | 1.84% | 16 |
|
|
2019
Q3 | $1.6B | Buy |
17,992,343
+1,048,300
| +6% | +$90.9M | 1.69% | 17 |
|
|
2019
Q2 | $1.4B | Sell |
16,944,043
-4,787,028
| -22% | -$375M | 1.39% | 21 |
|
|
2019
Q1 | $1.76B | Sell |
21,731,071
-1,167,323
| -5% | -$92M | 1.74% | 15 |
|
|
2018
Q4 | $1.74B | Buy |
22,898,394
+3,026,242
| +15% | +$236M | 1.95% | 15 |
|
|
2018
Q3 | $1.57B | Buy |
19,872,152
+10,235,068
| +106% | +$774M | 1.45% | 18 |
|
|
2018
Q2 | $677M | Buy |
+9,637,084
| New | +$693M | 0.66% | 44 |
|
|
2017
Q3 | – | Sell |
-991,651
| Closed | -$67.6M | – | 653 |
|
|
2017
Q2 | $67.6M | Buy |
991,651
+5,796
| +0.6% | +$378K | 0.07% | 229 |
|
|
2017
Q1 | $61.4M | Sell |
985,855
-158,640
| -14% | -$9.23M | 0.07% | 233 |
|
|
2016
Q4 | $62.5M | Buy |
1,144,495
+719,299
| +169% | +$40.8M | 0.07% | 231 |
|
|
2016
Q3 | $27.9M | Sell |
425,196
-2,400
| -0.6% | -$157K | 0.03% | 364 |
|
|
2016
Q2 | $25.8M | Sell |
427,596
-1,089,872
| -72% | -$63.3M | 0.03% | 373 |
|
|
2016
Q1 | $85.5M | Buy |
1,517,468
+17,908
| +1% | +$1.08M | 0.09% | 192 |
|
|
2015
Q4 | $102M | Sell |
1,499,560
-453,608
| -23% | -$29.7M | 0.1% | 168 |
|
|
2015
Q3 | $124M | Buy |
1,953,168
+610,661
| +45% | +$40.2M | 0.13% | 140 |
|
|
2015
Q2 | $85.5M | Buy |
1,342,507
+11,578
| +0.9% | +$793K | 0.08% | 233 |
|
|
2015
Q1 | $91.1M | Buy |
1,330,929
+378,400
| +40% | +$26.3M | 0.08% | 216 |
|
|
2014
Q4 | $67M | Buy |
+952,529
| New | +$68.2M | 0.06% | 279 |
|
|
2014
Q2 | – | Sell |
-1,132,321
| Closed | -$73.5M | – | 712 |
|
|
2014
Q1 | $73.5M | Buy |
+1,132,321
| New | +$73.1M | 0.07% | 257 |
|
Other funds holding AZN
EPGL
RG
SAM
CDDEC
MGP
Jennison Associates's AZN Position: Q2 2026 in Review
Jennison Associates increased its AstraZeneca (AZN) stake by 0.38% in Q2 2026, buying an estimated $480K and bringing the position to 666,497 shares worth $126M. The position accounts for 0.08% of the portfolio, ranked #127.
Jennison Associates first reported a position in AZN in Q1 2014 and has held it in 45 quarters since. The position peaked at $2.07B in Q2 2020. 906 funds tracked by Wall St. Rank hold AZN as of Q2 2026.
- Jennison Associates held 666,497 shares of AstraZeneca worth $126M as of Q2 2026.
- Jennison Associates bought 2,552 AstraZeneca shares in Q2 2026, an estimated $480K.
- AstraZeneca made up 0.08% of Jennison Associates's portfolio in Q2 2026, its #127 holding.
- Jennison Associates first reported a position in AstraZeneca in Q1 2014 and has held it in 45 quarters since.
- Jennison Associates's AstraZeneca position peaked at $2.07B in Q2 2020.
- 906 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2026.
Based on Jennison Associates's 13F filing for Q2 2026, filed 3 Aug 2026.